Drawing upon strong multi-jurisdictional capabilities- predominantly with Europe- the WilmerHale team is ‘calm under pressure’ when handling IPOs, follow-on public offerings, and complex SPAC transactions. Representing both issuers and managers, the practice shows a special focus on the medtech and medical industries, with the New York-based duo of Brian Johnson and Lisa Firenze leading the outfit. In Boston, Stuart Falber regularly counsels mature public companies and investment banks, and Molly Fox is a corporate finance expert, while Craig Hilts is knowledgeable on convertible debt offerings. Also in Boston, Cynthia Mazareas and Caroline Dotolo are also noted as key.
Legal 500 redaktioneller Kommentar
- Profil
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
- 'Scott Lunin is a thorough subject matter expert. Feel completely confident in his counsel. And he takes the time to explain complex matters. Had helped get through unique matters with NASDAQ.'
Kernmandanten
- Medtronic, Inc.
- State Street Corporation
- MKS Instruments, Inc.
- Analog Devices, Inc.
- Thermo Fisher Scientific
- Agios Pharmaceuticals
- MicroStrategy Incorporated
- Casella Waste Systems, Inc.
- McCormick & Company, Incorporated
- Choice Hotels International, Inc.
Highlight-Mandate
- Advised Medtronic in its public offering of €850 million aggregate principal amount of 3.650% Senior Notes due 2029, €850 million aggregate principal amount of 3.875% Senior Notes due 2036, €600 million aggregate principal amount of 4.150% Senior Notes due 2043 and €700 million aggregate principal amount of 4.150% Senior Notes due 2053.
- Advised Thermo Fisher Scientific as US special counsel in connection with its inaugural offer and sale of CHF-denominated bonds, in an offering that was the largest issuance by a foreign issuer of Swiss franc bonds in seven years, worth CHF $1.07 billion.
- Advised Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), in its agreement to sell its rights to its 15% royalty on potential $1 billion US net sales of Servier’s vorasidenib to Royalty Pharma.
Anwält*innen
Praxisleitung
Brian Johnson; Lisa Firenze
Weitere Kernanwält*innen
Stuart Falber; Molly Fox; Craig Hilts; Cynthia Mazareas; Caroline Dotolo; Scott Lunin